A Pharmacokinetic Study of the Coadministration of LY2216684 With Sertraline
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
LY2216684 is being studied as adjunctive treatment for major depressive disorder (MDD) in
participants who are partial responders to selective serotonin reuptake inhibitors (SSRIs).
Sertraline is a medication that is widely used to treat MDD and is a known substrate of
cytochrome P450s (CYP450s), including CYP450 2D6 (CYP2D6), CYP450 2C19 (CYP2C19), CYPP450 3A4
(CYP3A4), and a modest inhibitor of CYP2D6. Based on the diversity of hepatic metabolic
clearance pathways for LY2216684 and its elimination by the kidney, it is expected that
CYP2D6 inhibition by sertraline will not result in a substantial change in the
pharmacokinetic (PK) profile of LY2216684. LY2216684 is only known to be a moderate inhibitor
of CYP2C19, so it is unlikely that coadministration of sertraline with LY2216684 will result
in a clinically meaningful change in the PK of sertraline. This study is being conducted to
test these hypotheses.